Medpace account plan
Clinical research services
At a glance
Medpace: Cincinnati full-service clinical CRO for Phase I-IV trials, $2,530.2 million FY2025 revenue and about 6,600 employees in 46 countries.
Medpace Holdings, Inc. is a Cincinnati-based, full-service clinical contract research organization running Phase I-IV trials for biotechnology, pharmaceutical and medical device companies, and positions itself as a partner of choice for small and mid-sized biopharmaceutical companies. Its integrated offering spans medical leadership, trial management on its proprietary ClinTrak system, monitoring, regulatory affairs, biometrics, central and bioanalytical laboratories and Phase I clinics. FY2025 revenue was $2,530.2 million (+20.0%) and net income $451.1 million. It had about 6,600 employees across 46 countries at 30 September 2026, carries no debt and is listed on Nasdaq; founder August J. Troendle controls about 19.0% of the shares.
Business units
Oncology
$747.6 million FY2025 revenue (about 29.5%)The largest therapeutic area, growing every year shown; Q3 2026 revenue was $229.9 million, overtaking Metabolic for the quarter as the mix shifts back toward traditional oncology.
Metabolic
$745.0 million FY2025 revenue (about 29.4%)Fastest-growing area in FY2025, heavily weighted to obesity and diabetes, and the main driver of higher pass-through costs. Management expected its share of revenue to fall in 2026; nine-month 2026 revenue was $665.9 million.
Central Nervous System
$254.8 million FY2025 revenue (about 10.1%)One of the three areas behind FY2025 growth; Q3 2026 revenue rose to $83.6 million from $65.6 million.
Cardiology
$239.4 million FY2025 revenue (about 9.5%)Supported by the cardiovascular core laboratory; broadly stable, at $61.4 million in Q3 2026.
Antiviral and Anti-infective (AVAI)
$134.9 million FY2025 revenue (about 5.3%)A declining area, supported by central laboratory molecular and viral testing; $31.8 million in Q3 2026.
Other therapeutic areas
$408.5 million FY2025 revenue (about 16.1%)All other indications, slightly down in FY2025 and $100.0 million in Q3 2026.
Strategic priorities
- Grow Phase I-IV market share
- Expand mainly organically through the full-service model and therapeutic depth, with only "potentially highly selective bolt-on acquisitions and investments".
- Win rate and awards
- Process changes made late in 2025 to raise the win rate; net new business awards reached $873.4 million in Q3 2026 (+10.6%) and trailing 12-month awards grew 23.9%.
- Small and mid-sized biotech focus
- Large pharma "is not a focus"; purely functional (FSP) outsourcing is declined in favour of full-service projects.
- Hiring and retention
- Hiring growth in the mid to high single digits in 2026, with margin gains from retention and utilization rather than restructuring; headcount rose from about 6,200 to about 6,600 in nine months.
- Capital return
- A new buyback authorization of up to $1.0 billion until 31 December 2028, after $912.9 million of repurchases in 2025.
Latest results
In Q3 2026 revenue rose 8.5% to $716.0 million and GAAP net income to $137.5 million ($4.84 per diluted share), with EBITDA up 16.0% to $172.1 million (24.0% margin). Nine-month revenue was $2,129.9 million (+16.9%). Backlog reached $3,167.2 million (+5.6%), with $1,980.0-2,000.0 million expected to convert over the next twelve months. 2026 guidance is revenue of $2.835-2.855 billion (+12.0% to 12.8%), GAAP net income of $514.0-524.0 million and EBITDA of $638.0-652.0 million; 2027 guidance comes in February.
Investments and deals
- Cincinnati campus expansion
- A significant expansion of the Cincinnati campus will add about $20 million of operating costs in 2027; capital spending rose to 2.39% of revenue over nine months of 2026.
- Share repurchases
- 2,961,924 shares bought for $912.9 million in 2025 and 705,616 shares for $294.7 million in 2026; a new authorization of up to $1.0 billion was approved effective 20 October 2026.
- AI adoption
- First AI uses target efficiency across the organisation and data analytics for feasibility and site selection; management expects the investment to at least equal the benefits in 2026.
Challenges and risks
- Contract cancellations
- Q4 2025 backlog cancellations were the highest in over a year, and Q3 2026 cancellations were toward the higher end of the expected range, now driven mainly by product failure and safety signals.
- Customer and therapeutic concentration
- Top 5 and top 10 customers were roughly 31% and 39% of trailing 12-month revenue; several trials in one therapeutic class can be cancelled together.
- AI disruption
- The CEO calls AI, on the surface, a net negative for a service company paid to provide staff over a period of years; the 10-K also flags a competitive risk from under-investing in AI tools.
- Client acquisitions by large pharma
- When large pharma buys a biotech client, Medpace generally keeps the work but loses the client long term.
What leadership says
“The business environment remains strong”
“Cancellations were elevated again in Q4. Backlog cancellations in absolute and percent terms were the highest they've been in over a year.”
“some of the crazy approaches taken by some in the past few years have died out. I think we are kind of back to a normalized environment”
Where a supplier can help
- Site selection and feasibility analytics
- Tied to AI adoption, whose first uses include data analytics for feasibility and site selection: data and analytics providers for trial planning.
- Training and talent tools
- Tied to the hiring and retention priority: learning, recruiting and retention tools for a company that hires ahead and trains its own staff.
- Campus build-out and laboratory equipment
- Tied to the Cincinnati campus expansion: facilities, fit-out and laboratory suppliers.
- Patient recruitment
- Tied to the challenge of cancellations and the 10-K risk on investigator and patient recruitment: recruitment and retention services that keep studies on track.
- Biotech pipeline intelligence
- Tied to the small and mid-sized biotech focus and the win-rate priority: market intelligence that helps business development find funded sponsors.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Medpace?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Medpace Holdings, Inc. Annual Report on Form 10-K for fiscal year 2025
- Medpace is a Cincinnati-based, full-service clinical contract research organization (CRO) running Phase I-IV trials for the biotechnology, pharmaceutical and medical device industries, positioned as a partner of choice for small and mid-sized biopharmaceutical companies.
- FY2025 revenue was $2,530.2 million (+20.0% vs $2,109.1 million), income from operations $534.9 million and net income $451.1 million (FY2024: $404.4 million).
- Reimbursed out-of-pocket expenses (pass-throughs) rose 34.6% to $1,037.5 million; growth was driven by Metabolic, Oncology and Central Nervous System work.
- Net new business awards were $2,646.8 million (FY2024: $2,230.0 million); backlog reached $3,027.2 million (+4.3%), of which about $1,890.0-1,910.0 million is expected to convert to revenue in 2026.
- One reportable segment; revenue by therapeutic area: Oncology $747.6 million, Metabolic $745.0 million, Other $408.5 million, CNS $254.8 million, Cardiology $239.4 million, AVAI $134.9 million.
- About 6,200 employees across 46 countries; U.S. contracting entities account for about 99% of revenue.
- Top ten customers represent about 35.1% of net revenue, no customer above 10%.
- Capital return: 2,961,924 shares repurchased for $912.9 million in 2025; no debt; cash $497.0 million; $821.7 million of authorization left at year-end.
- Founder and CEO August J. Troendle controls about 19.0% of the shares; risks flagged include contract cancellations, backlog conversion, customer/therapeutic concentration and AI.
- Medpace Holdings, Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2026
- Q3 2026 revenue was $716.0 million (+8.5% vs $659.9 million); nine-month revenue $2,129.9 million (+16.9%).
- Q3 net income was $137.5 million (Q3 2025: $111.1 million); nine-month net income $382.7 million (vs $316.0 million).
- Net new business awards were $873.4 million in Q3 (vs $789.6 million) and $2,287.6 million over nine months (vs $1,910.2 million).
- Backlog was $3,167.2 million at 30 September 2026 (+5.6%); $1,980.0-2,000.0 million is expected to convert to revenue over the next twelve months.
- Growth came mainly from Metabolic, Oncology and CNS; Q3 Oncology revenue was $229.9 million and Metabolic $209.2 million.
- Reimbursed out-of-pocket expenses rose only 3.8% in Q3 (to $287.3 million) after +25.9% over nine months.
- About 6,600 employees across 46 countries; cash $705.3 million, no debt.
- 705,616 shares repurchased for $294.7 million in 2026, none in Q3; on 20 October 2026 the Board replaced the program with a new authorization of up to $1.0 billion.
- Medpace Holdings, Inc. Reports Third Quarter 2026 Results (press release, 8-K Exhibit 99.1)
- Q3 2026 revenue $716.0 million, up 8.5% (8.6% at constant currency), with a backlog conversion rate of 23.8%.
- Net new business awards $873.4 million, up 10.6%; backlog $3,167.2 million, up 5.6%.
- GAAP net income $137.5 million or $4.84 per diluted share (Q3 2025: $111.1 million, $3.86); net income margin 19.2%.
- EBITDA $172.1 million, up 16.0%, a 24.0% margin (22.5% a year earlier).
- Year to date: revenue $2,129.9 million (+16.9%), net income $382.7 million, EBITDA $474.9 million (22.3% margin).
- 2026 guidance: revenue $2.835-2.855 billion (+12.0% to 12.8%), GAAP net income $514.0-524.0 million, EBITDA $638.0-652.0 million, diluted EPS $17.97-18.32.
- New buyback authorization of up to $1.0 billion until 31 December 2028, replacing $527.0 million left on the old program; cash $705.3 million.
- Medpace Q3 2026 earnings call transcript
- CEO August Troendle: the business environment "remains strong"; net new business awards reached an all-time high and trailing 12-month awards grew 23.9%.
- No 2027 guidance until February, but Troendle sees "no large disconnect" between analyst consensus and Medpace's current modeling of 2027; Q4 awards and cancellations will decide it.
- Cancellations were "toward the higher end" of the expected range, now driven mainly by product failure and safety signals rather than funding.
- Mix is shifting back toward traditional oncology, with "a little bit less metabolic demand", though many metabolic opportunities are pending.
- Win-rate process changes made at the end of 2025 are judged "very successful"; pricing environment is "back to a normalized environment".
- CFO Kevin Brady: 2026 revenue guidance $2.835-2.855 billion, EBITDA $638-652 million; pass-throughs expected around 40-40.5% of revenue.
- A significant Cincinnati campus expansion will add about $20 million of operating costs in 2027.
- Top 5 and top 10 customers are roughly 31% and 39% of trailing 12-month revenue; large pharma work mostly follows acquired biotech clients.
- Medpace Q4 and full year 2025 earnings call transcript
- CEO August Troendle: Q4 2025 backlog cancellations were "the highest they've been in over a year", giving a net book-to-bill of 1.04; he rated the environment "adequate and headed in the right direction".
- Cancellations were widespread and skewed toward metabolic; metabolic, heavily obesity/diabetes, should decrease as a share of revenue in 2026.
- Full-year 2025: revenue $2.53 billion (+20%), EBITDA $557.7 million (+16.1%), net income $451.1 million, net awards $2.65 billion (+18.7%).
- 2026 guidance at the time: revenue $2.755-2.855 billion (+8.9% to 12.8%), EBITDA $605-635 million, EPS $16.68-17.50; pass-throughs 41-42% of revenue.
- Hiring to accelerate to mid-to-high single-digit growth in 2026; margin gains come from retention and utilization, not restructuring.
- On AI, Troendle expects no net productivity gain in 2026 and calls it, on the surface, "a net negative" for staff-based service companies over years; first uses target efficiency and feasibility/site selection.
- Top five and top 10 customers were roughly 25% and 35% of 2025 revenue; large pharma "is not a focus".
Questions about Medpace
What does Medpace do?
Medpace is a full-service clinical contract research organization that runs Phase I-IV trials for biotechnology, pharmaceutical and medical device companies, mainly small and mid-sized biopharma.
What is Medpace's revenue?
FY2025 revenue was $2,530.2 million, up 20.0%. For 2026 Medpace guides to $2.835-2.855 billion.
How many employees does Medpace have?
About 6,600 employees across 46 countries as of 30 September 2026, up from about 6,200 at the end of 2025.
Who leads Medpace?
Founder August J. Troendle is Chief Executive Officer, President and Chairman; Kevin M. Brady is Chief Financial Officer.
Which therapeutic areas matter most to Medpace?
Oncology and Metabolic each brought about 29% of FY2025 revenue, followed by Other areas, CNS, Cardiology and AVAI.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)